Federal lab technologies for detecting counterfeit medicines in supply chains

Counterfeit medicines can enter a legitimate distribution channel at several points: during manufacture, international shipping, repackaging, wholesale distribution or online sale. A falsified product may contain the wrong active ingredient, too little of it, a toxic substitute or no therapeutic ingredient at all. Detecting these products requires more than checking a package logo. It calls for analytical science, secure data systems and practical inspection tools that work across a fast-moving supply chain.

Federal laboratories in the United States have developed technologies that can help businesses, regulators and researchers identify suspicious medicines and verify product identity. Through the Federal Laboratory Consortium, Australian organisations can also learn how government-funded research is made available for licensing, testing partnerships and commercial development. The relevant capabilities range from portable chemical analysis to imaging, reference materials, sensors and authentication methods.

Why counterfeit medicine detection needs several layers

A medicine can appear genuine while failing a laboratory test for composition, strength or stability. Sophisticated counterfeiters may copy packaging, imitate batch numbers and use materials that look convincing to the naked eye. A robust detection programme therefore combines visual inspection with chemical, physical and digital checks.

Federal research can support each layer. Spectroscopic instruments may compare a tablet’s chemical signature with an approved reference. Chromatographic methods can identify active ingredients and contaminants. Imaging systems can examine print quality, tablet surfaces and microscopic features, while data tools can flag unusual movement through a distribution network.

The most useful solution depends on where an organisation operates. A border agency may need rapid, non-destructive screening for large consignments. A wholesaler may require a compact instrument for receiving checks. A quality-control laboratory may need highly sensitive confirmation equipment. These different settings create opportunities for commercial products built around federal laboratory research.

Technologies that reveal a medicine’s chemical identity

Near-infrared, Raman and other spectroscopic techniques can analyse tablets, capsules, powders and liquids with limited sample preparation. Each formulation produces a characteristic response based on its molecular structure. When the reading is compared with an authenticated library, an operator can identify a likely mismatch without waiting for a full laboratory assay.

Mass spectrometry and advanced chromatography provide deeper confirmation. They can distinguish an active pharmaceutical ingredient from a similar-looking substitute, detect unexpected fillers and identify degradation products. Such equipment is generally more expensive and requires trained staff, but it can provide defensible evidence when a suspect shipment is referred for enforcement or regulatory action.

Federal laboratories may also contribute reference materials, validated test procedures and measurement science. These resources matter because a screening device is only as reliable as its comparison data. A commercial developer could combine a federal analytical method with a rugged instrument, cloud-based reporting and a workflow designed for pharmacies or logistics hubs in Australia.

Portable screening at borders and distribution centres

Large central laboratories cannot examine every parcel or pallet entering the country. Portable analysers can give inspectors and supply-chain staff an initial result at a port, warehouse or courier facility. Handheld Raman and infrared devices, for example, may screen sealed containers or small samples without damaging a saleable consignment.

This approach is especially relevant to Australia’s geography. A shipment may arrive through Sydney or Melbourne, move through a national wholesaler in Brisbane, and then travel thousands of kilometres to a pharmacy in Perth, Darwin or a regional town. Rapid screening can help prioritise which consignments need controlled quarantine and full laboratory analysis rather than treating every shipment in the same way.

Automation can increase throughput in a warehouse, but it must be designed around safe human interaction and contamination control. Teams installing collaborative robots or automated inspection stations can review robot installation safety before integrating handling equipment with cameras, scanners and sampling devices. The aim is a repeatable process that protects workers while preserving chain-of-custody records.

Packaging, markings and digital authenticity

Chemical testing is only part of the picture. Counterfeiters often exploit packaging because cartons, labels and security seals can be reproduced at scale. Federal research in optical science, materials engineering and machine vision can help create or inspect features that are difficult to copy, including microprinting, spectral inks, covert patterns and tamper-evident structures.

A camera system can compare a package with an approved design and identify changes in fonts, colour registration, seal placement or serial-number format. The result becomes stronger when the image is linked to production and distribution records. A mismatch between a valid-looking serial number and its expected location, date or movement may reveal diversion or duplication.

Australia’s medicines market includes community pharmacies, hospital pharmacies, online sellers and large discount chains. Many consumers are accustomed to ordering products online or using home delivery, which increases the importance of packaging verification outside a traditional pharmacy counter. Any digital system must protect patient information and comply with Australian privacy obligations while giving authorised users enough data to investigate a suspicious product.

Connecting federal research with Australian needs

The Federal Laboratory Consortium provides a route into a broad network of American government laboratories and technology-transfer offices. Its technology transfer network can help businesses locate relevant inventions, laboratory expertise and opportunities for licensing or collaborative development. An Australian company may use the directory and technology listings to identify an analytical method, sensor platform or authentication technology suitable for local adaptation.

The commercial path can involve several stages. A company may first discuss technical details with a laboratory, assess intellectual-property rights, and conduct a feasibility study. It may then license a technology, form a research partnership or build a product around a federal method. Regulatory planning should begin early, because an instrument marketed as a quality-control aid may face different obligations from software used to make a therapeutic decision.

Entrepreneurs often provide the bridge between a promising laboratory result and a deployable product. The Federal Laboratory Consortium’s discussion of entrepreneurial technology transfer reflects the importance of commercial judgement, customer discovery and manufacturing knowledge. For an Australian developer, that could mean adapting a US-origin detection method to local wholesalers, TGA expectations, transport conditions and the needs of pharmacies serving remote communities.

Working within Australia’s regulatory environment

The Therapeutic Goods Administration regulates medicines under the Therapeutic Goods Act 1989 and maintains the Australian Register of Therapeutic Goods. Detection technology does not replace the TGA’s regulatory role, but it can support manufacturers, sponsors, importers and enforcement bodies that need evidence about product quality or provenance.

Australian Border Force and other agencies may encounter suspect products at international mail facilities, airports, seaports and cargo terminals. A screening system intended for these environments should produce clear results, preserve samples where possible and record who performed each action. Evidence handling is important when a suspected counterfeit is connected to an investigation, product recall or public-health warning.

Supply-chain software also needs to reflect local practice. The same product may pass through a licensed sponsor, a wholesaler, a hospital purchasing system and a community pharmacy before reaching a patient. Verification tools should accommodate Australian product identifiers, batch and expiry information, recalls and the requirements of the Pharmaceutical Benefits Scheme where relevant. They should also distinguish a genuine product affected by poor storage from a deliberately falsified medicine.

Making detection practical for pharmacies and patients

A pharmacy does not usually have the space, budget or staff time of a pharmaceutical manufacturer. Practical tools therefore need simple operation, minimal sample preparation and a result that can be understood quickly. A compact scanner, secure mobile application or tamper-evident inspection station could support receiving checks without interrupting dispensing.

Training remains essential. Staff should know how to isolate a questionable item, record its packaging and batch details, avoid returning it to stock, and escalate the matter through the appropriate channel. A device that produces an uncertain result must direct the user towards controlled follow-up rather than creating false confidence. Calibration, software updates and reference-library maintenance are also part of the operating model.

Patient behaviour affects the risk landscape. Australians may obtain medicines through hospital discharge services, suburban pharmacies, online marketplaces or personal importation. A detection programme can reduce harm by improving professional verification, but public-facing messages should avoid encouraging people to open sterile products or rely on informal visual checks. The strongest protection comes from a traceable, properly regulated supply chain supported by reliable analytical evidence.

Building a connected detection ecosystem

The most capable future systems will combine laboratory science with secure logistics data. A chemical screen can indicate that a tablet is inconsistent with its claimed formulation, while a digital record can show whether the package travelled through an authorised channel. Machine learning may help identify unusual purchasing or shipment patterns, provided the underlying data is accurate and decisions remain subject to human review.

Interoperability will determine whether these tools work across borders and organisations. Manufacturers, importers, wholesalers, pharmacies, laboratories and regulators need agreed formats for product identifiers, test results and incident records. Australian deployments may also need offline operation in areas with limited connectivity, resilient data storage and service arrangements that cover distant regional sites.

Federal lab technologies offer a foundation rather than a finished answer. Their value lies in making advanced measurement, materials science and engineering available for adaptation to real supply-chain conditions. With careful licensing, local validation and regulatory alignment, these capabilities can help Australian organisations detect falsified medicines earlier, reduce unsafe distribution and strengthen confidence in the products patients receive.